Biome to launch cholesterol reducing probiotic

What an incredible year it has been for Biome Australia Limited (ASX: BIO). Biome Activated Probiotics is now the fastest growing brand across the entire complementary medicine industry and the biggest growth brand in community pharmacy products, and there is plenty of scope for continued strong growth during the next 3-5 years. Moves are underway to expand into European markets and Biome is quickly moving towards becoming cash flow positive.

To cap off what has been an amazing year, the company announced yesterday that they will be launching Biome Cholesterol in the June quarter of 2024.  The market for treatments that lower cholesterol in Australia is massive, so this product has the potential to generate significant additional sales in the near term. More than 4 million Australians are reported to be living with cardiovascular diseases with high total cholesterol, high LDL cholesterol and low HDL cholesterol being major risk factors.

In a double blind, placebo controlled 12-week trial clinical trial, Biome Cholesterol reduced LDL (bad cholesterol) by 15% whilst increasing HDL (good cholesterol) by 7% compared to baseline. Overall, total cholesterol was reduced by 14%. Potential exists for Biome Cholesterol Probiotic to be used as an adjuvant alongside statins to support increased efficacy of treatment, or to reduce the dosage and side effects of this type of treatment. For people who don’t tolerate statins therapy, Biome Cholesterol Probiotic will provide physicians with an additional therapeutic option to help manage the cholesterol levels of these patients. The exclusive license covers Biome practitioner only distribution channels in Australia and New Zealand and will last for an initial period of 3 years.

Paul Hart

Canary Capital